Recruiting

Therapeutic Plasma Exchange

Sponsor:

MaxWell Clinic, PLC

Code:

NCT06079827

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimer's Disease and how quickly those biomarkers reappear after treatment.

Conditions

Alzheimer Disease

Study ID

NCT06079827

Start date

Mar 22, 2022

Status verified date

Oct, 2023

Completion date

Sep 1, 2025

Anticipated

Primary completion date

Sep 1, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Subject is scheduled to undergo their first TPE Procedure for a diagnosis of Alzheimer's Disease or previous mental/cognitive impairment
2. Mentally capable of understanding and completing informed consent for the study.

Exclusion Criteria:

1. Subject is unable or failed to return/provide blood specimen on days seven (7), fourteen (14) , twenty-one (21), and twenty-eight (28) (plus or minus 1 day on follow up draws) post plasma exchange
2. Subject is unable to provide informed consent.

Study Design

Enrollment

43 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • To ascertain if Therapeutic Plasma Exchange (TPE) reduces the presence of RNA biomarkers in a small sample of Alzheimer's patients. [ Time Frame: 28 days ]

Central Contacts and Locations

Locations

The MaxWell Clinic

Recruiting

Brentwood, Tennessee, United States, 37027

Contacts

Justin Davis

615-370-0091Justin@maxwellclinic.com

Cale T Queen, PhD

16153700091cale@maxwellclinic.com

Principal Investigator:

David H Haase, MD

More Information

Sponsor

MaxWell Clinic, PLC

Last update posted

Oct 12, 2023

Last verified

Oct, 2023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by MaxWell Clinic, PLC on 2023-10-12.